With tailwinds tied to last-minute IRA contributions coming to an end and markets turning lower into the weekend, investors may be looking for stocks in the bargain bin. While no one knows when the market will find its footing, buying these three stocks with a longtime frame of mind could be savvy.
No. 1: Regeneron Pharmaceuticals (REGN 0.61%)
Regeneron already markets the multibillion dollar generating Eylea, a drug used to treat wet age-related macular degeneration, and Praluent, a next-generation cholesterol-fighting drug, and it could notch FDA approval for two more drugs in the coming year that could really boost its top line.
Earlier this year, Regeneron and co-developer Sanofi reported that sarilumab outperformed the mega blockbuster Humira in rheumatoid arthritis, and more recently, the pair announced that their dupilumab successfully treated patients with eczema. These two autoimmune diseases each represent billion dollar opportunities for the company.
Given that Regeneron shares have dropped considerably in the past year and the company could potentially have four top selling drugs in its product lineup by the end of 2017, picking up this company's stock on sale may be smart.
No. 2: Gilead Sciences (GILD 0.90%)
Worry that a new hepatitis C drug from Merck & Co. could knock Gilead Sciences from its perch as the market share leader in the indication has weighed on shares this year, but it may be time to cozy back up with this top-tier biotech.
Gilead Sciences is about to report its first quarter results, and while those results could show a slight drop-off in sales of hepatitis C treatment Harvoni, the slip could prove temporary.
In June, the FDA will decide whether to approve Gilead Sciences' next-generation hep C drug, a pan-genotype therapy that delivers arguably best-in-class efficacy and safety, and that could remove the need for genotype testing someday.
Since Gilead Sciences remains the biggest player in HCV and this new therapy could further insulate it against its competitors, buying shares while they're off their peak and are trading at only 8.1 times forward EPS could pay off.
No. 3: Medivation, Inc. (MDVN)
Although Medivation has gained back some ground since falling on news that members of Congress were up in arms about the price of its top-selling prostate cancer drug, Xtandi, there could still be room to go higher.
Xtandi is a $2 billion per year therapy, and it continues to nudge away market share from competing blockbuster drugs, including J&J's Zytiga. Research that could expand Xtandi's use into breast cancer is well under way, and two additional drugs in trials could make this cancer pure-play the target of an acquirer.
Rumors are already circulating that Sanofi could be prepping a bid, and since Medivation has the unique distinction of being one of the few profitable mid cap biotechs out there, other companies with an interest in bolstering their presence in oncology could be interested too (Hint: Gilead Sciences).
Even if suitors don't line up to buy Medivation lock-stock-and-barrel, this company still only trading at 26 times forward earnings. That's pretty reasonable for a biotech that can grow its top and bottom line by double digit percentages in the future.